1. Home
  2. Protocols and Guidelines
  3. Current CAP Guidelines
  4. Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy

Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy

Background

The evidence-based clinical guideline “Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy” will help pathologists optimize testing methods to better identify and evaluate patients with cancer who may be eligible for immunotherapies known as checkpoint inhibitors.

This CAP guideline includes six recommendations and three good practice statements grounded in reviewed clinical evidence to specify which assay pathologists and oncologists should use to assess microsatellite instability (MSI)-high or mismatch repair (MMR) status. The recommendations impact testing for patients with colorectal, endometrial, gastroesophageal, small bowel, and other types of cancer. In addition, it provides guidance on the role of tumor mutational burden in MMR testing and the evaluation for Lynch Syndrome.

Guideline Information

Status: Active

Published ahead of print: August 3, 2022

Guideline Tools & Resources

Collaborators

Association for Molecular Pathology
Fight Colorectal Cancer

Review more upcoming CAP evidence-based guidelines by the Center.

Have a Question or Comment?

Send us an email.

Email the Center Right Arrow